1. SARS-CoV-2 suppresses host innate immunity  News-Medical.Net
  2. Sex differences in immune responses  Science Magazine
  3. View Full coverage on Google News
SARS-CoV-2, the virus that causes COVID-19, blocks the processes of innate immune activation that normally direct the production and/or signaling of type I interferon (IFN-I) by the infected cell and tissues.SARS-CoV-2, the virus that causes COVID-19, blocks the processes of innate immune activation that normally direct the production and/or signaling of type I interferon (IFN-I) by the infected cell and tissues.

SARS-CoV-2 suppresses host innate immunity

Evidence increasingly indicates that male sex is a risk factor for more severe disease and death from COVID-19. Male bias in COVID-19 mortality is observed in nearly all countries with available sex-disaggregated data, and the risk of death in males is ∼1.7 times higher than in females ([ 1 ][1]). Aging is strongly associated with higher risk of death in both sexes, but at all ages above 30 years, males have a significantly higher mortality risk, rendering older males the most vulnerable group ([ 1 ][1]). Sex differences are intertwined with differences in gender roles socially and with behavioral factors, which also influence COVID-19 incidence and outcomes. However, there are also possible biological mechanisms of male sex bias that affect the severity of COVID-19, particularly with respect to immune responses. Sex differences beyond sex organs are present across species and extend to physiological systems, including the immune system. Infection by different pathogens results in differential immune responses and disease outcomes by sex, and although the pattern depends on age and other host factors, male sex is more often associated with lower immune responses and higher susceptibility and/or vulnerability to infections in animals. This is generally also the case in humans ([ 2 ][2]): Male patients have higher viral loads for hepatitis B virus (HBV) and HIV ([ 2 ][2]). Conversely, females generally mount a more robust immune response to vaccines, such as influenza vaccines. However, the heightened immune responses in females can also lead to detrimental immunopathology in infections ([ 2 ][2]). The physiological response to virus infection is initiated when virus replication is detected by pattern recognition receptors. This leads to two antiviral programs by the infected cells: (i) cellular antiviral defense programs mediated by type I and type III interferons (IFNs) to limit viral replication and spread, and (ii) cytokine and chemokine production to recruit and coordinate immune cells, such as monocytes and neutrophils that can phagocytose and eliminate infected cells. Notably, COVID-19 is characterized by strong innate immune cytokine and chemokine responses despite the disproportionately low antiviral defense signature mediated by IFNs ([ 3 ][3]). Patients with severe COVID-19 exhibit high serum concentrations of proinflammatory cytokines and chemokines, with particularly high concentrations of interleukin-6 (IL-6) and the inflammasome-associated cytokines IL-1β and IL-18 ([ 4 ][4]). Exacerbated systemic inflammation is associated with extensive pulmonary pathology, including massive infiltration of monocytes and neutrophils. Increased neutrophil count is associated with poor clinical outcome ([ 5 ][5]). The robust induction of these inflammatory cytokines and cells may be a compensatory response to the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to evade IFN responses, which necessitates the engagement of IFN-independent defense mechanisms ([ 6 ][6]). The plasma concentrations of several key innate immune cytokines and chemokines, such as IL-8 and IL-18, are increased in male patients compared with female patients in the early phase of COVID-19. Conversely, female patients have higher plasma concentrations of type I IFN (IFNα) over the disease course ([ 7 ][7]). Notably, autoantibodies that inhibit type I IFN signaling have been reported in a subset of severely ill patients, the majority (94%) of whom were older males ([ 8 ][8]). By contrast, T cell activation at the early phase of SARS-CoV-2 infection is robust even in older female patients, whereas male patients have a significant decline with age. Male patients with poor T cell activation at the early phase of disease onset have worse COVID-19 outcomes, whereas no such difference is observed in female patients ([ 7 ][7]). What could be the potential underlying mechanism of this sex dimorphism in immune response? One culprit is the sex chromosomes: A substantial number of important immune-related genes are encoded on the X chromosome. Although one of the two copies of the X chromosome in females is usually epigenetically silenced [X chromosome inactivation (XCI)], some critical immune-related genes, including Toll-like receptor 7 [ TLR7 , whose viral RNA sensing elicits strong type I IFN production in its major producer, plasmacytoid dendritic cells (pDCs)], can escape from XCI in some proportion of cells. This makes the population “mosaic” for biallelic expression, which leads to higher gross expression of some immune-related genes in females ([ 9 ][9]). Human pDCs have also been reported to have higher expression of interferon regulatory factor 5 (IRF5) in females. Higher expression of these genes leads to more robust type I IFN responses in females, and this is one of the potential mechanisms involved in females' enhanced protection against viral infections, including COVID-19 ([ 1 ][1], [ 2 ][2]). Sex has a major impact on immune cell transcriptomes; immune cells or even the immune system are differentially affected by aging, depending on sex. Aging induces a decline in the proportion of naïve T cells that is more prominent in males, and B cells decline after age 65 only in males ([ 10 ][10]). Males have abrupt and drastic changes in the epigenetic landscape of their immune cells between ages 62 and 64, and subsequently males exhibit an accelerated immunosenescence phenotype that is characterized by enhanced innate proinflammatory gene expression and lower gene expression related to adaptive immunity, which could potentially predispose older males to hyperinflammation and poor adaptive immune responses. By contrast, major changes in the epigenetic landscape of immune cells occur in females 5 to 6 years later than in males, with this gap largely corresponding to the life span differences between sexes ([ 10 ][10]). It is notable that females generally mount more pronounced cytokine responses in viral infections, although this is not the case with COVID-19. Instead, males have higher plasma concentrations of innate proinflammatory cytokines such as IL-8 and IL-18 ([ 7 ][7]). This could be because patients who have severe disease are generally of older age, and the background transcriptomic and epigenetic sex differences in immune cells in these older individuals are possibly amplified and more explicitly manifested in the context of SARS-CoV-2 infection (see the figure). The other important biological factors are sex hormones. In a mouse model of SARS-CoV infection, higher mortality in male mice was observed and was attributed to the protective roles of the female sex hormone estrogen ([ 1 ][1]). Studies using various cell types and animal models have shown that the expression of angiotensin-converting enzyme 2 (ACE2), the host cell entry receptor for SARS-CoV-2, is modulated by estrogen ([ 1 ][1]). This likely occurs through transcriptional regulation by estrogen receptor signaling, although the detailed molecular mechanisms are yet to be identified and the consequences of the type of ACE2 modulation (up- or down-regulation) could be cell type– and context-dependent. Estrogen receptors are widely expressed by many cell types, including immune cells, and estrogen is a critical regulator of gene expression and functions in innate immune cells, including monocytes, macrophages, and dendritic cells, as well as in lymphocytes such as T helper 1/2 (TH1/2) cells, regulatory T cells (Tregs), and B cells. One of the major forms of estrogen, estradiol, has been shown to dampen the production of excessive innate inflammatory cytokines by monocytes and macrophages ([ 1 ][1]). Menopause is an independent risk factor for female patients, and concentrations of estradiol and anti-Müllerian hormone, which is produced by cells in developing follicles and is an endocrine marker for oocytes remaining in the ovaries (ovarian reserve), are inversely correlated with COVID-19 severity ([ 11 ][11]). Conversely, androgen-deprivation therapies for prostate cancer have been reported to reduce the risk for SARS-CoV-2 infection ([ 12 ][12]). Like estrogen receptors, androgen receptors are expressed widely among immune cells, regulating the transcription of various genes, and the outcome of their signaling has been shown to be generally immunosuppressive ([ 1 ][1]). ![Figure][13]</img> Sex differences in factors that affect infection and immunity in COVID-19 SARS-CoV-2 binds to ACE2 to initiate host cell entry. This activates the viral RNA sensors TLR3/7/8 and RIG-I–MDA-5, which induce secretion of IFNs and other inflammatory cytokines, leading to innate and adaptive immune responses. In each of these steps, sex differences may shape the antiviral immune response. GRAPHIC: V. ALTOUNIAN/ SCIENCE Despite the emerging understanding of sex differences of immune responses in COVID-19, many questions remain. Sex is not binary, and little is known regarding immune responses to viral infections, including COVID-19, in individuals with disorders of sex development (DSD) or transgender individuals. DSD describes congenital conditions in which the development of chromosomal, gonadal, and anatomical sex is atypical. For example, Klinefelter syndrome (also known as 47, XXY) results in phenotypes such as gynecomastia (enlarged breast tissue in males) and small testes with hypogonadism. This condition accompanies a series of comorbidities, in particular a high frequency of autoimmune diseases, such as systemic lupus erythematosus (SLE). The prevalence of SLE among Klinefelter syndrome patients is higher by a factor of 14 than among 46, XY males; this is comparable to its prevalence among 46, XX females, which suggests a gene dosage effect of the X chromosome ([ 13 ][14]). Additionally, transgender is a collective term encompassing those whose gender identities or gender roles differ from those typically associated with the sex they were assigned at birth. Little is known about the immune responses in these individuals, some of whom are undergoing gender reassignment hormone therapies. It is possible that DSD and transgender individuals mount distinct immune responses to viral infection in general and also in COVID-19. Sex differences in immunity also have implications for responses to SARS-CoV-2 vaccination or reinfection. Analysis of convalescent plasma showed that male sex, older age, and hospitalization for COVID-19 were associated with greater SARS-CoV-2 antibody titers ([ 14 ][15]). This could be related to increased disease severity in this demographic of patients, with increased viral load driving more B cell activation and antibody production. Alternatively, higher amounts of antiviral antibodies could be due to compensatory increases in antibody production due to suboptimal qualities of antibodies generated in older males, which are unable to neutralize the virus effectively. Antibodies with suboptimal neutralizing ability have the capacity to promote viral invasion into host cells such as macrophages [called antibody-dependent enhancement (ADE)]. However, there has been no clear evidence of ADE in COVID-19. With other viral infections, fatal diseases in dengue virus infection (dengue hemorrhagic fever and dengue shock syndrome) have been associated with ADE. Upon secondary infection with a virus of a serotype different from that of the primary infection, the fatalities from these severe diseases were primarily seen in adult females despite the male dominance in dengue hemorrhagic fever prevalence ([ 15 ][16]). The mechanism remains unknown but may be due to heightened inflammation in females, leading to capillary permeability. It is important that studies of COVID-19 patients report results in a sex-disaggregated manner, not only to elucidate differential disease pathogenesis, but also to enable a deeper understanding of this disease and the eventual development of better treatment and preventive strategies. It should be standard practice to collect and report sex-disaggregated data for this and for all infectious disease and vaccine studies in the future. 1. [↵][17]1. E. P. Scully et al ., Nat. Rev. Immunol. 20, 442 (2020). [OpenUrl][18][CrossRef][19][PubMed][20] 2. [↵][21]1. S. L. Klein, 2. K. L. Flanagan , Nat. Rev. Immunol. 16, 626 (2016). [OpenUrl][22][CrossRef][23][PubMed][24] 3. [↵][25]1. D. Blanco-Melo et al ., Cell 181, 1036 (2020). [OpenUrl][26][CrossRef][27][PubMed][28] 4. [↵][29]1. C. Lucas et al ., Nature 584, 463 (2020). [OpenUrl][30][CrossRef][31][PubMed][28] 5. [↵][32]1. J. Wang et al ., Front. Immunol. 11, 2063 (2020). [OpenUrl][33][CrossRef][34][PubMed][35] 6. [↵][36]1. S. Nish, 2. R. Medzhitov , Immunity 34, 629 (2011). [OpenUrl][37][CrossRef][38][PubMed][39][Web of Science][40] 7. [↵][41]1. T. Takahashi et al ., Nature 588, 315 (2020). [OpenUrl][42] 8. [↵][43]1. P. Bastard et al ., Science 370, eabd4585 (2020). [OpenUrl][44][Abstract/FREE Full Text][45] 9. [↵][46]1. M. Souyris et al ., Sci. Immunol. 3, eaap8855 (2018). [OpenUrl][47][Abstract/FREE Full Text][48] 10. [↵][49]1. E. J. Márquez et al ., Nat. Commun. 11, 751 (2020). [OpenUrl][50][CrossRef][51] 11. [↵][52]1. T. Ding et al ., Clin. Infect. Dis. 10.1093/cid/ciaa1022 (2020). 12. [↵][53]1. M. Montopoli et al ., Ann. Oncol. 31, 1040 (2020). [OpenUrl][54] 13. [↵][55]1. R. H. Scofield et al ., Arthritis Rheum. 58, 2511 (2008). [OpenUrl][56][CrossRef][57][PubMed][58][Web of Science][59] 14. [↵][60]1. S. L. Klein et al ., J. Clin. Invest. 130, 6141 (2020). [OpenUrl][61][CrossRef][62] 15. [↵][63]1. S. S. Sam et al ., PLOS Negl. Trop. Dis. 7, e2194 (2013). [OpenUrl][64][CrossRef][65][PubMed][66] [1]: #ref-1 [2]: #ref-2 [3]: #ref-3 [4]: #ref-4 [5]: #ref-5 [6]: #ref-6 [7]: #ref-7 [8]: #ref-8 [9]: #ref-9 [10]: #ref-10 [11]: #ref-11 [12]: #ref-12 [13]: pending:yes [14]: #ref-13 [15]: #ref-14 [16]: #ref-15 [17]: #xref-ref-1-1 "View reference 1 in text" [18]: {openurl}?query=rft.jtitle%253DNat.%2BRev.%2BImmunol.%26rft.volume%253D20%26rft.spage%253D442%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fs41577-020-0348-8%26rft_id%253Dinfo%253Apmid%252F32528136%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [19]: /lookup/external-ref?access_num=10.1038/s41577-020-0348-8&link_type=DOI [20]: /lookup/external-ref?access_num=32528136&link_type=MED&atom=%2Fsci%2F371%2F6527%2F347.atom [21]: #xref-ref-2-1 "View reference 2 in text" [22]: {openurl}?query=rft.jtitle%253DNat.%2BRev.%2BImmunol.%26rft.volume%253D16%26rft.spage%253D626%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fnri.2016.90%26rft_id%253Dinfo%253Apmid%252F27546235%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [23]: /lookup/external-ref?access_num=10.1038/nri.2016.90&link_type=DOI [24]: /lookup/external-ref?access_num=27546235&link_type=MED&atom=%2Fsci%2F371%2F6527%2F347.atom [25]: #xref-ref-3-1 "View reference 3 in text" [26]: {openurl}?query=rft.jtitle%253DCell%26rft.volume%253D181%26rft.spage%253D1036%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.cell.2020.04.026%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [27]: /lookup/external-ref?access_num=10.1016/j.cell.2020.04.026&link_type=DOI [28]: /lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fsci%2F371%2F6527%2F347.atom [29]: #xref-ref-4-1 "View reference 4 in text" [30]: {openurl}?query=rft.jtitle%253DNature%26rft.volume%253D584%26rft.spage%253D463%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fs41586-020-2588-y%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [31]: /lookup/external-ref?access_num=10.1038/s41586-020-2588-y&link_type=DOI [32]: #xref-ref-5-1 "View reference 5 in text" [33]: {openurl}?query=rft.jtitle%253DFront.%2BImmunol.%26rft.volume%253D11%26rft.spage%253D2063%26rft_id%253Dinfo%253Adoi%252F10.3389%252Ffimmu.2020.02063%26rft_id%253Dinfo%253Apmid%252F33013872%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [34]: /lookup/external-ref?access_num=10.3389/fimmu.2020.02063&link_type=DOI [35]: /lookup/external-ref?access_num=33013872&link_type=MED&atom=%2Fsci%2F371%2F6527%2F347.atom [36]: #xref-ref-6-1 "View reference 6 in text" [37]: {openurl}?query=rft.jtitle%253DImmunity%26rft.volume%253D34%26rft.spage%253D629%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.immuni.2011.05.009%26rft_id%253Dinfo%253Apmid%252F21616433%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [38]: /lookup/external-ref?access_num=10.1016/j.immuni.2011.05.009&link_type=DOI [39]: /lookup/external-ref?access_num=21616433&link_type=MED&atom=%2Fsci%2F371%2F6527%2F347.atom [40]: /lookup/external-ref?access_num=000291456500001&link_type=ISI [41]: #xref-ref-7-1 "View reference 7 in text" [42]: {openurl}?query=rft.jtitle%253DNature%26rft.volume%253D588%26rft.spage%253D315%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [43]: #xref-ref-8-1 "View reference 8 in text" [44]: {openurl}?query=rft.jtitle%253DScience%26rft_id%253Dinfo%253Adoi%252F10.1126%252Fscience.abd4585%26rft_id%253Dinfo%253Apmid%252F32972996%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [45]: /lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6Mzoic2NpIjtzOjU6InJlc2lkIjtzOjE3OiIzNzAvNjUxNS9lYWJkNDU4NSI7czo0OiJhdG9tIjtzOjIyOiIvc2NpLzM3MS82NTI3LzM0Ny5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30= [46]: #xref-ref-9-1 "View reference 9 in text" [47]: {openurl}?query=rft.jtitle%253DScience%2BImmunology%26rft.stitle%253DSci.%2BImmunol.%26rft.aulast%253DSouyris%26rft.auinit1%253DM.%26rft.volume%253D3%26rft.issue%253D19%26rft.spage%253Deaap8855%26rft.epage%253Deaap8855%26rft.atitle%253DTLR7%2Bescapes%2BX%2Bchromosome%2Binactivation%2Bin%2Bimmune%2Bcells%26rft_id%253Dinfo%253Adoi%252F10.1126%252Fsciimmunol.aap8855%26rft_id%253Dinfo%253Apmid%252F29374079%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [48]: /lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTA6ImltbXVub2xvZ3kiO3M6NToicmVzaWQiO3M6MTM6IjMvMTkvZWFhcDg4NTUiO3M6NDoiYXRvbSI7czoyMjoiL3NjaS8zNzEvNjUyNy8zNDcuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9 [49]: #xref-ref-10-1 "View reference 10 in text" [50]: {openurl}?query=rft.jtitle%253DNat.%2BCommun.%26rft.volume%253D11%26rft.spage%253D751%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fs41467-020-14396-9%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [51]: /lookup/external-ref?access_num=10.1038/s41467-020-14396-9&link_type=DOI [52]: #xref-ref-11-1 "View reference 11 in text" [53]: #xref-ref-12-1 "View reference 12 in text" [54]: {openurl}?query=rft.jtitle%253DAnn.%2BOncol.%26rft.volume%253D31%26rft.spage%253D1040%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [55]: #xref-ref-13-1 "View reference 13 in text" [56]: {openurl}?query=rft.jtitle%253DArthritis%2Band%2Brheumatism%26rft.stitle%253DArthritis%2BRheum%26rft.aulast%253DScofield%26rft.auinit1%253DR.%2BH.%26rft.volume%253D58%26rft.issue%253D8%26rft.spage%253D2511%26rft.epage%253D2517%26rft.atitle%253DKlinefelter%2527s%2Bsyndrome%2B%252847%252CXXY%2529%2Bin%2Bmale%2Bsystemic%2Blupus%2Berythematosus%2Bpatients%253A%2Bsupport%2Bfor%2Bthe%2Bnotion%2Bof%2Ba%2Bgene-dose%2Beffect%2Bfrom%2Bthe%2BX%2Bchromosome.%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fart.23701%26rft_id%253Dinfo%253Apmid%252F18668569%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [57]: /lookup/external-ref?access_num=10.1002/art.23701&link_type=DOI [58]: /lookup/external-ref?access_num=18668569&link_type=MED&atom=%2Fsci%2F371%2F6527%2F347.atom [59]: /lookup/external-ref?access_num=000259055400036&link_type=ISI [60]: #xref-ref-14-1 "View reference 14 in text" [61]: {openurl}?query=rft.jtitle%253DJ.%2BClin.%2BInvest.%26rft.volume%253D130%26rft.spage%253D6141%26rft_id%253Dinfo%253Adoi%252F10.1172%252FJCI142004%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [62]: /lookup/external-ref?access_num=10.1172/JCI142004&link_type=DOI [63]: #xref-ref-15-1 "View reference 15 in text" [64]: {openurl}?query=rft.jtitle%253DPLOS%2BNegl.%2BTrop.%2BDis.%26rft.volume%253D7%26rft.spage%253De2194%26rft_id%253Dinfo%253Adoi%252F10.1371%252Fjournal.pntd.0002194%26rft_id%253Dinfo%253Apmid%252F23658849%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [65]: /lookup/external-ref?access_num=10.1371/journal.pntd.0002194&link_type=DOI [66]: /lookup/external-ref?access_num=23658849&link_type=MED&atom=%2Fsci%2F371%2F6527%2F347.atom

Sex differences in immune responses | Science

A troubling new study has identified four key ways in which coronavirus can "target" men's reproductive systems and could be devastating news for couples hoping to have a babyA troubling new study has identified four key ways in which coronavirus can "target" men's reproductive systems and could be devastating news for couples hoping to have a baby

Covid poses 'global threat' to male fertility with virus able to change shape of sperm - Daily Star